This study is to assess how oral emraclidine moves through the body of healthy elderly adult participants, and assess adverse events, and tolerability.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Participants Experiencing Adverse Events
Timeframe: Up to approximately 50 days
Number of Participants with Clinical Significant Change From Baseline in Vital Sign Measurements
Timeframe: Up to approximately 20 days
Number of Participants with Clinical Significant Change from Baseline in Electrocardiogram (ECG)
Timeframe: Up to approximately 20 days
Number of Participants with Clinical Significant Change in Physical Examinations
Timeframe: Up to approximately 20 days
Number of Participants with Clinical Significant Change in Clinical Laboratory Test Results Like Hematology will be Assessed
Timeframe: Up to approximately 20 days
Change from Baseline in Columbia-Suicide Severity Rating Scale (C-SSRS)
Timeframe: Up to approximately 20 days
Change From Baseline in Abnormal Involuntary Movement Scale (AIMS)
Timeframe: Up to approximately 20 days
Change From Baseline in Barnes Akathisia Rating Scale (BARS)
Timeframe: Up to approximately 20 days
Change From Baseline in Simpson-Angus Scale (SAS)
Timeframe: Up to approximately 20 days
Maximum Observed Plasma Concentration (Cmax) of Emraclidine
Timeframe: Up to approximately 20 days
Maximum Observed Plasma Concentration (Cmax) of Metabolite (CV-0000364)
Timeframe: Up to approximately 20 days
Time to Cmax (Tmax) of Emraclidine
Timeframe: Up to approximately 20 days
Time to Cmax (Tmax) of Metabolite (CV-0000364)
Timeframe: Up to approximately 20 days
Area Under the Concentration-Time Curve from Time 0 to Time t (AUCt) of Emraclidine
Timeframe: Up to approximately 20 days
Area Under the Concentration-Time Curve from Time 0 to Time t (AUCt) Metabolite (CV-000036)
Timeframe: Up to approximately 20 days
Area under the plasma concentration-time curve over the dosing interval (AUCtau) of Emraclidine
Timeframe: Up to approximately 20 days
Minimum plasma concentration (Cmin) of Emraclidine
Timeframe: Up to approximately 20 days
Minimum plasma concentration (Cmin) of Metabolite (CV-0000364)
Timeframe: Up to approximately 20 days
Average plasma concentration (Cavg) of Emraclidine
Timeframe: Up to approximately 20 days
Average plasma concentration (Cavg) of Metabolite (CV-0000364)
Timeframe: Up to approximately 20 days
Metabolite to Parent Ratio (MRCmax) of Emraclidine
Timeframe: Up to approximately 20 days
Metabolite to Parent Ratio (MRCmax) of Metabolite (CV-0000364)
Timeframe: Up to approximately 20 days
Metabolite to Parent Ratio (MRAUCtau) of Emraclidine
Timeframe: Up to approximately 20 days
Metabolite to Parent Ratio (MRAUCtau) of Metabolite (CV-000036)
Timeframe: Up to approximately 20 days
Terminal Phase Elimination Half-Life (t1/2) of Emraclidine
Timeframe: Up to approximately 20 days
Terminal Phase Elimination Half-Life (t1/2) of Metabolite (CV-000036)
Timeframe: Up to approximately 20 days
Apparent terminal phase elimination constant (β) of Emraclidine
Timeframe: Up to approximately 20 days
Apparent terminal phase elimination constant (β) of Metabolite (CV-0000364)
Timeframe: Up to approximately 20 days
Peak-to-trough ratio (PTR) of Emraclidine
Timeframe: Up to approximately 20 days
Peak-to-trough ratio (PTR) of Metabolite (CV-000036)
Timeframe: Up to approximately 20 days
Accumulation ratio for Cmax (RacCmax) of Emraclidine
Timeframe: Up to approximately 20 days
Accumulation ratio for Cmax (RacCmax) of Metabolite (CV-0000364)
Timeframe: Up to approximately 20 days
Accumulation ratio for AUCtau (RacAUCtau) of Emraclidine
Timeframe: Up to approximately 20 days
Accumulation ratio for AUCtau (RacAUCtau) of Metabolite (CV-0000364)
Timeframe: Up to approximately 20 days
Apparent Clearance of Drug from Plasma (CL/F) of Emraclidine
Timeframe: Up to approximately 20 days
Apparent Volume of Distribution DuringTerminal Phase (Vz/F) of Emraclidine
Timeframe: Up to approximately 20 days
Area under the plasma concentration-time curve over the dosing interval (AUCtau) of Metabolite (CV-0000364)
Timeframe: Up to approximately 20 days